Latest Pharma Insights
Coultreon Raises $125m To Take Lead SIK3 Inhibitor Into Phase II
A team that worked on the lead program and its underlying drug discovery platform at Galapagos will take COL-5671 into Phase II in psoriasis and ulcerative colitis.
Scrip - April 28, 2026
A team that worked on the lead program and its underlying drug discovery platform at Galapagos will take COL-5671 into Phase II in psoriasis and ulcerative colitis.
Scrip - April 28, 2026
Church & Dwight Partners With Stada To Enter Eurasia
Stada will launch C&D brands like Batiste dry shampoo, Hero acne treatment patches and Trojan condoms in markets across Eurasia, including Kazakhstan and Armenia.
HBW Insight - April 28, 2026
Stada will launch C&D brands like Batiste dry shampoo, Hero acne treatment patches and Trojan condoms in markets across Eurasia, including Kazakhstan and Armenia.
HBW Insight - April 28, 2026
Medtronic Catheter Shows Promise in Treating Dangerous Heart Disorder
Medtronic's Sphere-9 catheter kept nearly two-thirds of high-risk heart attack survivors free from a dangerous arrhythmia six months after treatment, early data show.
Medtech Insight - April 28, 2026
Medtronic's Sphere-9 catheter kept nearly two-thirds of high-risk heart attack survivors free from a dangerous arrhythmia six months after treatment, early data show.
Medtech Insight - April 28, 2026
Investors Declare Revolution The Winner In Pan-RAS Skirmish With Erasca
Safety and efficacy doubts and legal action from its more advanced rival Revolution have seen Erasca’s share price slide.
Scrip - April 28, 2026
Safety and efficacy doubts and legal action from its more advanced rival Revolution have seen Erasca’s share price slide.
Scrip - April 28, 2026
Novartis CEO Calls For ‘Complete Rethink’ On Europe Pricing
Vas Narasimhan has reiterated his concerns about European governments which that adopt policies "that really don't enable companies like ours to continue to invest.”
Scrip - April 28, 2026
Vas Narasimhan has reiterated his concerns about European governments which that adopt policies "that really don't enable companies like ours to continue to invest.”
Scrip - April 28, 2026
GDUFA IV Talks Reach Tentative Agreement; America First Application Fee Waiver Added
The modified proposal would allow generic sponsors referencing US-based API and FDF manufacturing in the application to receive a one-time ANDA application fee waiver, potentially saving hundreds of thousands of dollars.
Generics Bulletin - April 28, 2026
The modified proposal would allow generic sponsors referencing US-based API and FDF manufacturing in the application to receive a one-time ANDA application fee waiver, potentially saving hundreds of thousands of dollars.
Generics Bulletin - April 28, 2026
Kisqali and Pluvicto Help Soften Novartis’s Patent Expiry Pain
CEO Vas Narasimhan is confident about life at the Swiss giant post-Entresto.
Scrip - April 28, 2026
CEO Vas Narasimhan is confident about life at the Swiss giant post-Entresto.
Scrip - April 28, 2026
Nokia Rides The ‘AI Supercycle Wave’ In APAC
Nokia has partnered with the Asia Regulatory Professional Association in a pilot to boost Asia-Pacific students’ AI knowledge and capabilities. Its start coincided with Nokia’s 6G partnership with NVIDIA, heralding the “AI-native wireless era.”
Medtech Insight - April 28, 2026
Nokia has partnered with the Asia Regulatory Professional Association in a pilot to boost Asia-Pacific students’ AI knowledge and capabilities. Its start coincided with Nokia’s 6G partnership with NVIDIA, heralding the “AI-native wireless era.”
Medtech Insight - April 28, 2026
Off-Patent Firms Appeal EU Court’s Ruling On The Individual Impact Of UWWTD
The European off-patent drug sector continues to fight against the urban wastewater treatment directive, now heading to the EU's highest court.
Generics Bulletin - April 28, 2026
The European off-patent drug sector continues to fight against the urban wastewater treatment directive, now heading to the EU's highest court.
Generics Bulletin - April 28, 2026
Lenacapavir Rollout Builds Toward Pivotal 2027 Generics Shift
Gilead Sciences has secured expanded backing from PEPFAR and the Global Fund to scale lenacapavir access, bridging supply gaps ahead of a planned generic rollout beginning in 2027.
Generics Bulletin - April 28, 2026
Gilead Sciences has secured expanded backing from PEPFAR and the Global Fund to scale lenacapavir access, bridging supply gaps ahead of a planned generic rollout beginning in 2027.
Generics Bulletin - April 28, 2026
Stock Watch: Light And Shade For Sanofi; More Darkness For Roche
Sanofi’s continued portfolio reclassifications could not detract from its over-dependence on a single product. Roche had worse results than Sanofi and was quick to blame foreign currency effects, but more fundamental issues were probably to blame.
Scrip - April 28, 2026
Sanofi’s continued portfolio reclassifications could not detract from its over-dependence on a single product. Roche had worse results than Sanofi and was quick to blame foreign currency effects, but more fundamental issues were probably to blame.
Scrip - April 28, 2026
Canada’s Apotex Makes Bold US Move With Cumberland Pharmaceuticals Deal
Apotex is set to acquire Cumberland Pharmaceuticals’ US line of branded pharmaceuticals and create a new platform to deliver specialty medicines that improve quality of patient care.
Generics Bulletin - April 28, 2026
Apotex is set to acquire Cumberland Pharmaceuticals’ US line of branded pharmaceuticals and create a new platform to deliver specialty medicines that improve quality of patient care.
Generics Bulletin - April 28, 2026
Oruka Clears The Skyrizi Bar With Phase II Plaque Psoriasis Data
Oruka’s Phase IIa data from IL-23p19 inhibitor exceeds the efficacy bar seen with AbbVie’s Skyrizi and matches that of UCB’s Bimzelx.
Scrip - April 28, 2026
Oruka’s Phase IIa data from IL-23p19 inhibitor exceeds the efficacy bar seen with AbbVie’s Skyrizi and matches that of UCB’s Bimzelx.
Scrip - April 28, 2026
Kyorin Joins Daito Plan To Stabilize Japanese Generics
Kyorin will transfer its core generics unit, plants and related assets into a Daito-led joint venture platform aimed at stabilizing Japan’s shortage-hit generic drug supply chain, while Kyorin refocuses on innovative medicines.
Generics Bulletin - April 28, 2026
Kyorin will transfer its core generics unit, plants and related assets into a Daito-led joint venture platform aimed at stabilizing Japan’s shortage-hit generic drug supply chain, while Kyorin refocuses on innovative medicines.
Generics Bulletin - April 28, 2026
BeOne Obtains Global Rights to Huahui Health’s Trispecifics For Up To $1.53bn
Beijing-based Huahui Health out-licenses preclinical anti-PD-1/CTLA-4/VEGF-A trispecific antibodies to BeOne Medicines for up to $1.53bn, but several other Chinese contenders in the class are chasing, including CStone, which may soon land a cross-border deal for its Phase II asset.
Scrip - April 28, 2026
Beijing-based Huahui Health out-licenses preclinical anti-PD-1/CTLA-4/VEGF-A trispecific antibodies to BeOne Medicines for up to $1.53bn, but several other Chinese contenders in the class are chasing, including CStone, which may soon land a cross-border deal for its Phase II asset.
Scrip - April 28, 2026
Over The Counter: Cracking China’s Consumer Health Market, With QIVA Global’s Ellie Adams
QIVA Global's Ellie Adams joins the Over The Counter podcast to share her insider perspective on what it really takes to crack China's consumer healthcare market.
HBW Insight - April 28, 2026
QIVA Global's Ellie Adams joins the Over The Counter podcast to share her insider perspective on what it really takes to crack China's consumer healthcare market.
HBW Insight - April 28, 2026
RAPS 2026 Preview: EU Medtech Regulation At A Crossroads
Updates to MDR, IVDR and the AI Act will be front of mind at this year’s Regulatory Affairs Professionals Society conference in Lisbon.
Medtech Insight - April 28, 2026
Updates to MDR, IVDR and the AI Act will be front of mind at this year’s Regulatory Affairs Professionals Society conference in Lisbon.
Medtech Insight - April 28, 2026
CanWell Advances First HER2-Targeting, Dual Cytotoxic Payload ADC Into Phase I
CanWell CEO Henry Yu explains the China- and US-based biotech’s pick of an MMAE-exatecan dual-payload combination, which is expected to help its HER2-targeting antibody-drug conjugate to more potently overcome the resistance to the single payload used in Enhertu.
Scrip - April 28, 2026
CanWell CEO Henry Yu explains the China- and US-based biotech’s pick of an MMAE-exatecan dual-payload combination, which is expected to help its HER2-targeting antibody-drug conjugate to more potently overcome the resistance to the single payload used in Enhertu.
Scrip - April 28, 2026
Podcast: Genyro’s Adrian Woolfson On Artificial Biological Intelligence And Genome Writing
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026
Boehringer Reports First Phase III Results For Survodutide In Obesity – But Is It Enough?
Boehringer’s Zealand-partnered GLP-1/glucagon agonist delivered significant weight loss in topline SYNCHRONIZE-1 data, but it remains to be seen if it is competitive with other dual agonists.
Scrip - April 28, 2026
Boehringer’s Zealand-partnered GLP-1/glucagon agonist delivered significant weight loss in topline SYNCHRONIZE-1 data, but it remains to be seen if it is competitive with other dual agonists.
Scrip - April 28, 2026
With ‘Low Hanging Fruit’ Of Conventional OTC Switches Picked Clean, ACNU Seeds New US Crop
OTC switches “have provided clinical benefits to consumers and reduced healthcare costs. However, as time has gone on, the low hanging fruit have switched,” says Karen Murry, acting director of FDA’s Office of Nonprescription Drugs.
HBW Insight - April 28, 2026
OTC switches “have provided clinical benefits to consumers and reduced healthcare costs. However, as time has gone on, the low hanging fruit have switched,” says Karen Murry, acting director of FDA’s Office of Nonprescription Drugs.
HBW Insight - April 28, 2026
History Lesson On Establishing Two Drug Classes Opens Look At Future Of OTC Access In US
“Essentially, nonprescription is the default status in the US. A drug is nonprescription unless it has to be prescription,” FDA ONPD acting director Karen Murry explains at public meeting on making more drugs available OTC.
HBW Insight - April 28, 2026
“Essentially, nonprescription is the default status in the US. A drug is nonprescription unless it has to be prescription,” FDA ONPD acting director Karen Murry explains at public meeting on making more drugs available OTC.
HBW Insight - April 28, 2026
Coultreon Raises $125m To Take Lead SIK3 Inhibitor Into Phase II
A team that worked on the lead program and its underlying drug discovery platform at Galapagos will take COL-5671 into Phase II in psoriasis and ulcerative colitis.
Scrip - April 28, 2026
A team that worked on the lead program and its underlying drug discovery platform at Galapagos will take COL-5671 into Phase II in psoriasis and ulcerative colitis.
Scrip - April 28, 2026
Investors Declare Revolution The Winner In Pan-RAS Skirmish With Erasca
Safety and efficacy doubts and legal action from its more advanced rival Revolution have seen Erasca’s share price slide.
Scrip - April 28, 2026
Safety and efficacy doubts and legal action from its more advanced rival Revolution have seen Erasca’s share price slide.
Scrip - April 28, 2026
Novartis CEO Calls For ‘Complete Rethink’ On Europe Pricing
Vas Narasimhan has reiterated his concerns about European governments which that adopt policies "that really don't enable companies like ours to continue to invest.”
Scrip - April 28, 2026
Vas Narasimhan has reiterated his concerns about European governments which that adopt policies "that really don't enable companies like ours to continue to invest.”
Scrip - April 28, 2026
Kisqali and Pluvicto Help Soften Novartis’s Patent Expiry Pain
CEO Vas Narasimhan is confident about life at the Swiss giant post-Entresto.
Scrip - April 28, 2026
CEO Vas Narasimhan is confident about life at the Swiss giant post-Entresto.
Scrip - April 28, 2026
Stock Watch: Light And Shade For Sanofi; More Darkness For Roche
Sanofi’s continued portfolio reclassifications could not detract from its over-dependence on a single product. Roche had worse results than Sanofi and was quick to blame foreign currency effects, but more fundamental issues were probably to blame.
Scrip - April 28, 2026
Sanofi’s continued portfolio reclassifications could not detract from its over-dependence on a single product. Roche had worse results than Sanofi and was quick to blame foreign currency effects, but more fundamental issues were probably to blame.
Scrip - April 28, 2026
Oruka Clears The Skyrizi Bar With Phase II Plaque Psoriasis Data
Oruka’s Phase IIa data from IL-23p19 inhibitor exceeds the efficacy bar seen with AbbVie’s Skyrizi and matches that of UCB’s Bimzelx.
Scrip - April 28, 2026
Oruka’s Phase IIa data from IL-23p19 inhibitor exceeds the efficacy bar seen with AbbVie’s Skyrizi and matches that of UCB’s Bimzelx.
Scrip - April 28, 2026
BeOne Obtains Global Rights to Huahui Health’s Trispecifics For Up To $1.53bn
Beijing-based Huahui Health out-licenses preclinical anti-PD-1/CTLA-4/VEGF-A trispecific antibodies to BeOne Medicines for up to $1.53bn, but several other Chinese contenders in the class are chasing, including CStone, which may soon land a cross-border deal for its Phase II asset.
Scrip - April 28, 2026
Beijing-based Huahui Health out-licenses preclinical anti-PD-1/CTLA-4/VEGF-A trispecific antibodies to BeOne Medicines for up to $1.53bn, but several other Chinese contenders in the class are chasing, including CStone, which may soon land a cross-border deal for its Phase II asset.
Scrip - April 28, 2026
CanWell Advances First HER2-Targeting, Dual Cytotoxic Payload ADC Into Phase I
CanWell CEO Henry Yu explains the China- and US-based biotech’s pick of an MMAE-exatecan dual-payload combination, which is expected to help its HER2-targeting antibody-drug conjugate to more potently overcome the resistance to the single payload used in Enhertu.
Scrip - April 28, 2026
CanWell CEO Henry Yu explains the China- and US-based biotech’s pick of an MMAE-exatecan dual-payload combination, which is expected to help its HER2-targeting antibody-drug conjugate to more potently overcome the resistance to the single payload used in Enhertu.
Scrip - April 28, 2026
Boehringer Reports First Phase III Results For Survodutide In Obesity – But Is It Enough?
Boehringer’s Zealand-partnered GLP-1/glucagon agonist delivered significant weight loss in topline SYNCHRONIZE-1 data, but it remains to be seen if it is competitive with other dual agonists.
Scrip - April 28, 2026
Boehringer’s Zealand-partnered GLP-1/glucagon agonist delivered significant weight loss in topline SYNCHRONIZE-1 data, but it remains to be seen if it is competitive with other dual agonists.
Scrip - April 28, 2026
Medtronic Catheter Shows Promise in Treating Dangerous Heart Disorder
Medtronic's Sphere-9 catheter kept nearly two-thirds of high-risk heart attack survivors free from a dangerous arrhythmia six months after treatment, early data show.
Medtech Insight - April 28, 2026
Medtronic's Sphere-9 catheter kept nearly two-thirds of high-risk heart attack survivors free from a dangerous arrhythmia six months after treatment, early data show.
Medtech Insight - April 28, 2026
Nokia Rides The ‘AI Supercycle Wave’ In APAC
Nokia has partnered with the Asia Regulatory Professional Association in a pilot to boost Asia-Pacific students’ AI knowledge and capabilities. Its start coincided with Nokia’s 6G partnership with NVIDIA, heralding the “AI-native wireless era.”
Medtech Insight - April 28, 2026
Nokia has partnered with the Asia Regulatory Professional Association in a pilot to boost Asia-Pacific students’ AI knowledge and capabilities. Its start coincided with Nokia’s 6G partnership with NVIDIA, heralding the “AI-native wireless era.”
Medtech Insight - April 28, 2026
RAPS 2026 Preview: EU Medtech Regulation At A Crossroads
Updates to MDR, IVDR and the AI Act will be front of mind at this year’s Regulatory Affairs Professionals Society conference in Lisbon.
Medtech Insight - April 28, 2026
Updates to MDR, IVDR and the AI Act will be front of mind at this year’s Regulatory Affairs Professionals Society conference in Lisbon.
Medtech Insight - April 28, 2026
Church & Dwight Partners With Stada To Enter Eurasia
Stada will launch C&D brands like Batiste dry shampoo, Hero acne treatment patches and Trojan condoms in markets across Eurasia, including Kazakhstan and Armenia.
HBW Insight - April 28, 2026
Stada will launch C&D brands like Batiste dry shampoo, Hero acne treatment patches and Trojan condoms in markets across Eurasia, including Kazakhstan and Armenia.
HBW Insight - April 28, 2026
Over The Counter: Cracking China’s Consumer Health Market, With QIVA Global’s Ellie Adams
QIVA Global's Ellie Adams joins the Over The Counter podcast to share her insider perspective on what it really takes to crack China's consumer healthcare market.
HBW Insight - April 28, 2026
QIVA Global's Ellie Adams joins the Over The Counter podcast to share her insider perspective on what it really takes to crack China's consumer healthcare market.
HBW Insight - April 28, 2026
With ‘Low Hanging Fruit’ Of Conventional OTC Switches Picked Clean, ACNU Seeds New US Crop
OTC switches “have provided clinical benefits to consumers and reduced healthcare costs. However, as time has gone on, the low hanging fruit have switched,” says Karen Murry, acting director of FDA’s Office of Nonprescription Drugs.
HBW Insight - April 28, 2026
OTC switches “have provided clinical benefits to consumers and reduced healthcare costs. However, as time has gone on, the low hanging fruit have switched,” says Karen Murry, acting director of FDA’s Office of Nonprescription Drugs.
HBW Insight - April 28, 2026
History Lesson On Establishing Two Drug Classes Opens Look At Future Of OTC Access In US
“Essentially, nonprescription is the default status in the US. A drug is nonprescription unless it has to be prescription,” FDA ONPD acting director Karen Murry explains at public meeting on making more drugs available OTC.
HBW Insight - April 28, 2026
“Essentially, nonprescription is the default status in the US. A drug is nonprescription unless it has to be prescription,” FDA ONPD acting director Karen Murry explains at public meeting on making more drugs available OTC.
HBW Insight - April 28, 2026
GDUFA IV Talks Reach Tentative Agreement; America First Application Fee Waiver Added
The modified proposal would allow generic sponsors referencing US-based API and FDF manufacturing in the application to receive a one-time ANDA application fee waiver, potentially saving hundreds of thousands of dollars.
Generics Bulletin - April 28, 2026
The modified proposal would allow generic sponsors referencing US-based API and FDF manufacturing in the application to receive a one-time ANDA application fee waiver, potentially saving hundreds of thousands of dollars.
Generics Bulletin - April 28, 2026
Off-Patent Firms Appeal EU Court’s Ruling On The Individual Impact Of UWWTD
The European off-patent drug sector continues to fight against the urban wastewater treatment directive, now heading to the EU's highest court.
Generics Bulletin - April 28, 2026
The European off-patent drug sector continues to fight against the urban wastewater treatment directive, now heading to the EU's highest court.
Generics Bulletin - April 28, 2026
Lenacapavir Rollout Builds Toward Pivotal 2027 Generics Shift
Gilead Sciences has secured expanded backing from PEPFAR and the Global Fund to scale lenacapavir access, bridging supply gaps ahead of a planned generic rollout beginning in 2027.
Generics Bulletin - April 28, 2026
Gilead Sciences has secured expanded backing from PEPFAR and the Global Fund to scale lenacapavir access, bridging supply gaps ahead of a planned generic rollout beginning in 2027.
Generics Bulletin - April 28, 2026
Canada’s Apotex Makes Bold US Move With Cumberland Pharmaceuticals Deal
Apotex is set to acquire Cumberland Pharmaceuticals’ US line of branded pharmaceuticals and create a new platform to deliver specialty medicines that improve quality of patient care.
Generics Bulletin - April 28, 2026
Apotex is set to acquire Cumberland Pharmaceuticals’ US line of branded pharmaceuticals and create a new platform to deliver specialty medicines that improve quality of patient care.
Generics Bulletin - April 28, 2026
Kyorin Joins Daito Plan To Stabilize Japanese Generics
Kyorin will transfer its core generics unit, plants and related assets into a Daito-led joint venture platform aimed at stabilizing Japan’s shortage-hit generic drug supply chain, while Kyorin refocuses on innovative medicines.
Generics Bulletin - April 28, 2026
Kyorin will transfer its core generics unit, plants and related assets into a Daito-led joint venture platform aimed at stabilizing Japan’s shortage-hit generic drug supply chain, while Kyorin refocuses on innovative medicines.
Generics Bulletin - April 28, 2026
Podcast: Genyro’s Adrian Woolfson On Artificial Biological Intelligence And Genome Writing
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026